NCT06441630

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 251 (estimated)
• Sponsor: Addpharma Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Detailed description

Essential Hypertension

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	AD-227A	Per Oral, 1 Tablet, Once a day for 8 weeks
DRUG	AD-227B	Per Oral, 1 Tablet, Once a day for 8 weeks
DRUG	AD-227C	Per Oral, 1 Tablet, Once a day for 8 weeks
DRUG	Placebo of AD-227B	Per Oral, 1 Tablet, Once a day for 8 weeks
DRUG	Placebo of AD-227C	Per Oral, 1 Tablet, Once a day for 8 weeks

Timeline

• Start date: 2024-07-31
• Primary completion: 2025-09-01
• Completion: 2025-09-01
• First posted: 2024-06-04
• Last updated: 2025-02-04

Locations

1 site across 1 country: South Korea